Gregory Larsen, MD
Urology · Marrero, LANPI 1548497860
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.4%. 2025 is the largest year on record at $4,392, 2.3 times the $1,890 reported in 2019.
Across 120 payments — averaging $85.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Telix Pharmaceuticals$2K
- Neotract Inc.$2K
- Teleflex LLC$2K
- Procept Biorobotics Corporation$1K
- Bayer$924
- Mission Medical Distribution, LLC$390
- plus $2K from 27 others
What the payments were for
- Consulting fees$8728%
- Travel & lodging$4,54744%
- Food & beverage$4,68146%
- Education$1682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Telix Pharmaceuticals | 6 | $1,992 |
| Neotract Inc. | 15 | $1,935 |
| Teleflex LLC | 15 | $1,744 |
| Procept Biorobotics Corporation | 15 | $1,211 |
| Bayer | 4 | $924 |
| Mission Medical Distribution, LLC | 1 | $390 |
| Astellas Pharma US Inc | 6 | $238 |
| Photocure Inc | 1 | $200 |
| Pfizer | 14 | $191 |
| Boston Scientific | 2 | $189 |
| Ferring Pharmaceuticals Inc. | 2 | $185 |
| Cook Medical LLC | 2 | $152 |
| Sumitomo Pharma America, Inc. | 7 | $138 |
| Janssen Scientific Affairs, LLC | 1 | $97 |
| Merck | 2 | $89 |
| Urogen Pharma, Inc. | 4 | $83 |
| Endo USA, Inc. | 3 | $54 |
| Coloplast | 2 | $53 |
| KARL Storz Endoscopy-america | 2 | $52 |
| AbbVie | 2 | $35 |
| Novartis | 1 | $34 |
| AstraZeneca | 2 | $34 |
| Conmed Corporation | 1 | $33 |
| Immunitybio, Inc. | 1 | $28 |
| Olympus America Inc. | 1 | $27 |
| Calyxo, Inc. | 1 | $25 |
| Hollister Incorporated | 1 | $24 |
| 180 Medical, Inc. | 1 | $22 |
| Mission Pharmacal Company | 1 | $22 |
| Tolmar, Inc. | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $18 |
| Urovant Sciences Inc | 1 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$2,936
- ILLUCCIX$1,913
- AquaBeam Robotic System$959
- Xofigo$872
- Cysview$200
- ADSTILADRIN$164
- AMS 700 CXR RTE KIT$138
- LITHO 150$128
- UroLift System$101
How this compares
$10,268 in reported general payments places this provider in the 80th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 189 | $114,920 |
| GemtesaVibegron | 36 | $26,849 |
| Solifenacin Succinate | 162 | $3,688 |
| Tamsulosin Hcl | 344 | $2,750 |
| Testosterone Cypionate | 58 | $1,598 |
| Finasteride | 131 | $1,370 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 48 | $962 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $334 |
| Dutasteride | 14 | $322 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $298 |
| Oxybutynin Chloride | 21 | $212 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $94 |
| Ciprofloxacin Hcl | 20 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $238 | $114,920189 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $138 | $26,84936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 199 urology providers in Louisiana.
Other urology in Marrero
- Wesley BryanMarrero$15K
- Jon GlassMarrero$15K
- Pablo LabadieMarrero$13K
- Matthew StrainMarrero$11K
- Richard VanlangendonckNew Orleans$289K
- Gerard HenryBossier City$256K
- Ralph HendersonShreveport$211K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Sunil PurohitCovington$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.